Exagamglogene autotemcel, based on CRISPR-Cas9 gene editing of BCL11A enhancer via electroporation (with the commercial name of CASGEVY), was approved by EMA in 2023 and FDA in 2023/2024 for both SCD and transfusion-dependent β-thalassemia [136]. This evidence concerns the gene BCL11A and Schnyder corneal dystrophy.